[Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)]. 1977

T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann

21 patients with primary hyperlipoproteinemias of type IIb and IV were treated for 8 weeks with placebo, 8 weeks with 0.3 g butylbiguanide and 1.5 g clofibrate/day and then for 8 weeks with 1.5 g clofibrate/day. In 12 patients a second placebo phase of 8 weeks followed. After 8 weeks of combined treatment with butylbiguanide and clofibrate the serum triglycerides decreased from 725 mg to 269 mg/100 ml. During the following period of clofibrate treatment the serum triglycerides increased after 4 and 8 weeks to 326 mg and 306 mg/100 ml respectively. The combined treatment with 0.3 g butylbiguanide and 1.5 g clofibrate/day is more effective in lowering elevated serum triglycerides and cholesterol than 1.5 g clofibrate alone.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002026 Buformin An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation. Butylbiguanide,1-Butylbiguanide,Adebit,Gliporal,Silubin,Silubin Retard,1 Butylbiguanide,Retard, Silubin
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol

Related Publications

T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
March 1976, Klinische Wochenschrift,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
December 1973, Deutsche medizinische Wochenschrift (1946),
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
October 1979, Clinica chimica acta; international journal of clinical chemistry,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
January 1980, Arzneimittel-Forschung,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
March 1976, Deutsche medizinische Wochenschrift (1946),
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
January 1974, Giornale italiano di cardiologia,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
September 1976, MMW, Munchener medizinische Wochenschrift,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
January 1972, Polish medical journal,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
February 1978, Medizinische Klinik,
T Koschinsky, and F A Gries, and P Schwandt, and P Weisweiler, and W Hansen, and J Nijssen, and R Beckmann
August 1977, Klinische Wochenschrift,
Copied contents to your clipboard!